Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: Post-hoc analysis of a prospective study

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Prats, Merche ^a   Font, Ramon ^a   García, Carmen ^a   Cabré, Carmen ^a   Jariod, Manel ^a   Vea, Alberto Martinez ^a  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

Author keywords

Chronic kidney disease; Ferric carboxymaltose; Fibroblast growth factor 23; Hypophosphatemia; Iron deficiency anaemia

Indexed keywords

CALCITRIOL; CALCIUM; FERRIC CARBOXYMALTOSE; FERRITIN; FIBROBLAST GROWTH FACTOR 23; HEMOGLOBIN; PARATHYROID HORMONE; PHOSPHATE; TRANSFERRIN; BIOLOGICAL MARKER; FERRIC ION; FIBROBLAST GROWTH FACTOR; MALTOSE;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MEGADOSE; FEMALE; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOPHOSPHATEMIA; IRON DEFICIENCY ANEMIA; IRON THERAPY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; SIDE EFFECT; THYROID HORMONE METABOLISM; TRANSFERRIN BLOOD LEVEL; VITAMIN BLOOD LEVEL; VITAMIN METABOLISM; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; MIDDLE AGED; PROSPECTIVE STUDY; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; FERRIC COMPOUNDS; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; MALTOSE; MIDDLE AGED; PHOSPHATES; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84880941446     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-167     Document Type: Article

References (48)

1. Iron status and haemoglobin level in chronic renal insufficiency. Hsu CY, McCulloch CE, Curhan GC, J Am Soc Nephrol 2002 13 2783 2786 10.1097/01.ASN.0000034200.82278.DC 12397050 (Pubitemid 35216049)
2. Iron supplementation to treat anemia in patients with chronic kidney disease. Besarab A, Coyne DW, Nat Rev Nephrol 2010 6 699 710 10.1038/nrneph.2010.139 20956992
3. Iron supplementation in the non-dialysis chronic kidney disease(ND-CKD) patients: oral or intravenous? Macdougall IC, Curr Med Res Opin 2010 26 473 482 10.1185/03007990903512461 20014980
4. Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Vaziri ND, Am J Kidney Dis 2013 61 992 1000 10.1053/j.ajkd.2012.10.027 23375852
5. Hemodialysis-associated hemosiderosis in the era of erythropoiesis- stimulating agents: a MRI study. Rostoker G, Griuncelli M, Loridon C, Couprie R, Benmaadi A, Bounhiol C, Roy M, Machado G, Janklewicz P, Drahi G, Dahan H, Cohen Y, Am J Med 2012 125 991 999 10.1016/j.amjmed.2012.01.015 22998881
6. Clinical aspects of iron use in the anemia of kidney disease. Hörl WH, J Am Soc Nephrol 2007 18 382 393 10.1681/ASN.2006080856 17229908 (Pubitemid 46193303)
7. Clinical use of intravenous iron: administration, efficacy, and safety. Auerbach M, Ballard H, Hematology Am Soc Hematol Educ Program 2010 2010 338 347 10.1182/asheducation-2010.1.338 21239816
8. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study. Covic A, Mircescu G, Nephrol Dial Transplant 2010 25 2722 2730 10.1093/ndt/gfq069 20190247
9. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Lysen-Williamson KA, Keating GM, Drugs 2009 69 739 756 10.2165/00003495- 200969060-00007 19405553
10. Safety and tolerability of ferric carboxymaltose(FCM) for tratment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients. Grimmelt AC, Cohen CD, Fehr T, Serra AL, Wüthrich RP, Clin Nephrol 2009 71 125 129 19203504
11. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis- dependent chronic kidney disease patients. Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD, Nephrol Dial Transplant 2011 26 1599 15607 10.1093/ndt/gfq613 20929915
12. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Seid MH, Derman RJ, Baker JB, Bnach W, Goldberg C, Rogers F, Am J Obstet Gynecol 2008 199 435.e1 435.e7 10.1016/j.ajog.2008.07.046
13. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Van Wyck DB, Mangione AM, Morrison J, Hadley PE, Jehle JA, Goodnough LT, Transfusion 2009 49 2719 2728 10.1111/j.1537-2995.2009.02327.x 19682342
14. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study. Charytan C, Bernardo MV, Koch TA, Butcher A, Morris D, Bregman DB, Nephrol Dial Transplant 2013 28 953 964 10.1093/ndt/gfs528 23222534
15. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide. Another form of FGF23-related hypophosphatemia. Shimizu Y, Tada Y, Yamaucho M, Okamoto T, Suzuki H, Ito N, Fukumoto S, Sugimoto T, Fujita T, Bone 2009 45 814 816 10.1016/j.bone.2009.06.017 19555782
16. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. Shouten BJ, Hunt PJ, Livesy JH, Frampton CM, Soule SG, J Clin Endocrinol Metab 2009 94 2332 2337 10.1210/jc.2008-2396 19366850
17. Effects of intravenous administration of iron preparations on the metabolism of phosphorus. Imamura K, Fukuoka Acta Med 1984 75 316 326 6489911
18. Iron isomaltoside 1000: a new high dose option for parenteral iron therapy. Kalra PA, Bock K, Meldal M, Port J Nephrol Hypert 2012 26 13 24
19. Cefotetan-induced haemolytic anemia causing severe hypophosphatemia. Mohammed S, Knoll S, Van Amberg A, Mennes PA, Am J Hematol 1994 46 369 370 10.1002/ajh.2830460422 8037194 (Pubitemid 24243887)
20. Severe hypophosphatemia during hematopoietic reconstitution after allogenic peripheral blood stem cell transplantation. Steiner M, Steiner B, Wilhelm S, Freund M, Schuff-Werner P, Bone Marroww Transplant 2000 25 1015 1016 10.1038/sj.bmt.1702407 (Pubitemid 30255739)
21. Hereditary spherocytosis associated with severe hypophosphatemia in patients recovering from aplastic crisis. Sahara N, Tamashima S, Ihara M, Rinsho Ketsueki 1998 39 387 391
22. Effect of saccharated ferric oxide and iron dextran on the metabolism of phosphorus in rats. Sanai T, Oochi N, Okada M, Imamura K, Okuda S, Ida M, J Lab Clin Med 2005 146 25 29 10.1016/j.lab.2005.02.015 16025088 (Pubitemid 40982016)
23. Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy due to nephropathy. Sato K, Shiraki M, Endocrine J 1998 45 431 439 10.1507/endocrj.45.431 (Pubitemid 28477653)
24. Low molecular weight iron dextran increases fibroblast growth factor-23 concentration together with parathyroid hormone decrease in hemodialyzed patients. Hryszko T, Rydzewska-Rosolowska A, Brzoski S, Koc-Zorawska E, Mysliwiec M, Ther Apher Dial 2012 16 146 151 10.1111/j.1744-9987.2011.01037.x 22458393
25. Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients. Takeda Y, Komaba H, Goto S, Fuji H, Umezu M, Hasegawa H, Fujimori A, Nishioka M, Nishi S, Fukagawa M, Am J Nephrol 2011 33 421 426 10.1159/000327019 21502756
26. Carboximaltosa férrica y estrés oxidativo en pacientes con enfermedad renal crónica prediálisis: efectos a corto y largo plazo. Prats M, Font R, Gutierrez, Nogués MR, Benito Y, Abejaro S, Garcia C, Romeu M, Martinez Vea A, Nefrologia 2011 31 Supp 2 58 21270914
27. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, Kassem M, Rackoff P, Zimering M, Dalkin A, Drobny E, Colussi G, Shaker JL, Hoogendoorn EH, Hui SH, Econs MJ, J Clin Endocrinol Metab 2006 91 2055 2061 10.1210/jc.2005-2105 16551733 (Pubitemid 43854981)
28. Chronic Kidney Disease Collaboration: sing standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F, Ann Intern Med 2006 145 247 254 10.7326/0003-4819-145-4-200608150-00004 16908915 (Pubitemid 46768608)
29. A comparative study of the physicochemical properties of iron isomaltoside 1000(Monofer§ssup§R§esup§), a new intravenous iron preparation and its clinical implications. Jahn MR, Andreasen HB, Fütterer S, Nawroth T, Schünemann V, Kolb U, Hofmeister W, Muñoz M, Bock K, Meldal M, Langguth P, Eur J Pharm Biopharm 2011 78 480 491 10.1016/j.ejpb.2011.03.016 21439379
30. Iron polymaltose-induced FGF23 elevation complicated by hypophosphatemic osteomalacia. Schoulten BJ, Doogue MP, Soule SG, Hunt PJ, Ann Clin Biochem 2009 46 167 169 10.1258/acb.2008.008151 19151167
31. Iron accumulation in human chronic kidney disease. Nankivell BJ, Boadle RA, Harris DCH, Am J Kidney Dis 1992 20 580 584 1462986 (Pubitemid 23031708)
32. Dietary protein alters tubular iron accumulation after partial nephrectomy. Nankivell BJ, Tay Y-C, Boadley RA, Harris DCH, Kidney Int 1994 45 1006 1013 10.1038/ki.1994.136 8007569 (Pubitemid 24234717)
33. Iron infusion and deposition in the kidney. Tolouian R, Rajabi B, Boman D, Bilbao J, Gupta J, Clin Nephrol 2013 79 237 240 23182397
34. Parenteral iron nephrotoxicity: Potential mechanisms and consequences. Zager RA, Johnson AC, Hanson SY, Kidney In 2004 66 144 156 10.1111/j.1523-1755. 2004.00716.x (Pubitemid 38870090)
35. The effects of iron on FGF23-mediated Ca-P metabolism in CKD patients. Deger SM, Erten Y, Pasaoglu OT, Derici UB, Reis KA, Onec K, Pasaoglu H, Clin Exp Nephrol 2013 17 416 423 10.1007/s10157-012-0725-0 23180041
36. Clinical usefulness of measurement of fibroblast growth factor 23(FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inove D, Minagawa M, Sugimoto T, Yamauchi M, Michigami T, Matsumoto T, Bone 2008 42 1235 1239 10.1016/j.bone.2008.02.014 18396126
37. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. Wolf M, Koch TA, Bregman DB, J Bone Miner Res 2013 28 1793 1803 10.1002/jbmr.1923 23505057
38. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. Imel EA, Peacock M, Gray AK, Padgett LD, Hui SL, Econs MJ, J Clin Endocrinol Metab 2011 96 3541 3549 10.1210/jc.2011-1239 21880793
39. Iron deficiency drives an autosomal dominant hypophosphatemic rickets(ADHR) phenotype in fibroblast growth factor-23(Fgf23) knock-in mice. Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, Robling AG, Stayrook KR, Jideonwo V, Magers MJ, Garringer HJ, Vidal R, Chan RJ, Goodwin CB, Hui SL, Peacock M, White KE, Proc Natl Acad Sci USA 2011 108 1146 E1155 10.1073/pnas.1110905108 22006328
40. The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commerical assays. Durham BH, Joseph F, Bailey LM, Fraser WD, Ann Clin Biochem 2007 44 463 466 10.1258/000456307781646102 17761032 (Pubitemid 351724655)
41. Mechanism of FGF23 processing in fibrous dysplasia. Bhattacharyya N, Wiench M, Dumitrescu C, Connolly BM, Bugge TH, Patel HV, Gafni RI, Cherman N, Cho M, Hager GL, Collins MT, J Bone Miner Res 2012 27 1132 1141 10.1002/jbmr.1546 22247037
42. Intact fibroblast growth factor-23 and fragments in plasma from gambian children. Braithwaite B, Bruggraber SF, Prentice A, Osteoporos Int 2013 24 1121 1124 10.1007/s00198-012-2029-3 22648001
43. FGF23 is correlated with iron status but not with inflammation, and decrease after iron supplementation: a supplementary study. Braithwaite B, Prentice AM, Doherty C, Prentice A, Int J Pediatr Endocrinol 2012 1 27
44. Excess iron inhibits osteoblast metabolism. Yamasaki K, Hagiwara H, Toxicol Lett 2009 191 21 215
45. Inhibitory effects of iron on bone morphogenetic protein.2-induced osteoblastogenesis. Yang Q, Jian J, Abramson SB, Huang X, J Bone Miner Res 2011 26 1188 1196 10.1002/jbmr.337 21308772
46. Bone formation regulates circulating concentrations of fibroblast growth factor 23. Samadfam R, Richard C, Nguyen-Yamamoto L, Bolivar I, Goltzman D, Endocrinology 2009 150 4835 4845 10.1210/en.2009-0472 19819968
47. Fibroblast growth factor 23 is a counterregulatory phosphaturic hormone for vitamin D. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, pi M, Quarles LD, J Am Soc Nephrol 2006 17 1305 1315 10.1681/ASN.2005111185 16597685 (Pubitemid 43673410)
48. Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol. Hansen D, Rasmussen K, Pedersen SM, Rasmussen LM, Brandi L, Nephrol Dial Transplant 2012 27 2263 2269 10.1093/ndt/gfr668 22140123